Can a Follow-Up drug deepen remission in myeloma patients?
NCT ID NCT06523621
First seen Jun 27, 2026 · Last updated Jul 14, 2026 · Updated 2 times
Summary
This study is for people with relapsed multiple myeloma who did not get a complete response after CAR-T cell therapy (idecabtagene vicleucel). Researchers want to see if adding nivolumab, an immunotherapy drug, can improve the depth of response. The trial is in Phase 2 and currently enrolling only 1 participant. The goal is to achieve a complete or stringent complete response.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Levine Cancer Institute
Charlotte, North Carolina, 28204, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?
- A guided path back to work after blood cancer: a trial tests the impact